FDA OK for Life Therapeutics' tetanus serum
Tuesday, 15 February, 2005
Life Therapeutics' (formerly Gradipore, ASX: LFE) US subsidiary Life Sera has received FDA approval to begin collecting tetanus hyperimmune serum for use as a prophylactic treatment following potential exposure to the tetanus toxin.
The product may bring US$2 million of sales into the company this calendar year. It is the third new product to be produced by Life Sera in the last three years and the second licensed product since the business was acquired by Life Therapeutics a year ago.
Last week, Life Therapeutics said its Life Bioprocess division in Sydney had completed the evaluation of its Gradiflow technology for the purification of high quality transgenic IgG for US-based company Hematech.
The technology was shown to be scalable and also to efficacious at removing both viral and DNA contaminants during the separation process, meeting regulatory requirements for biological manufacturing processes.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
